CSL Behring has announced the availability of DNA1 Advanced Alpha-1 Screening, this is a new test that aims to improve diagnosis of Alpha-1 Antitrypsin Deficiency (Alpha-1). Launched during Alpha-1 Awareness Month, DNA1 is the only comprehensive Alpha-1 test available that identifies known and unknown clinically relevant genetic variants to help physicians achieve an accurate diagnosis.
Read more: http://www.cslbehring.com/newsroom/Innovative-Alpha-1-Test-Aims-to-Improve-Diagnosis
This follows on from the AlphaKit Quickscreen device which was announced at the European Respiratory Society 2013 Congress in Barcelona. The testing device was developed by scientists working for Grifols.
This device is a quick way for physicians and healthcare providers to screen patients with COPD for Alpha-1. The Quickscreen requires a few drops of blood to detect the presence of the Z protein that is responsible for most severe Alpha-1 cases. The result is available within 15 minutes. It is anticipated that the kit will be available in several European countries in early 2014